Previous studies analyzing cerebrospinal fluid (CSF) neurodegeneration markers, namely, Aβ42, Aβ40, total tau, and phosphorylated tau, in CAA patients focused on comparison with patients with Alzheimer ́s disease or with healthy controls.5 This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.